Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Sponsor
National Cancer Institute, Naples
Study ID
NCT02633189
Phase
PHASE3
Status
Unknown

Conditions

  • Non-squamous Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    given orally 150 mg daily
  • Bevacizumab — DRUG
    15 mg/kg intravenously every 21 days.

Study Details

The purpose of this study is to test whether the combination of bevacizumab and erlotinib can prolong progression free survival as compared with erlotinib alone as first-line treatment in patients with non small cell lung cancer (NSCLC) with activating mutation of EGFR.

Key Dates

First listed
Dec 17, 2015
Start date
Apr 30, 2016
Status verified
Mar 2023
Primary completion
Dec 31, 2023
Completion
Jul 31, 2024

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: erlotinib and bevacizumab
  • Active Comparator: erlotinib

Primary Outcome Measure

progression free survival [ Time Frame: up to 2 years ]

Related Studies